ZDHHC5 and neoplasm: Although 2-BP, a non-specific palmitoylation inhibitor, has been employed in preclinical studies to suppress tumor formation by targeting ZDHHC5 (63, 64, 65, 66), its broader applicability as a therapeutic agent remains limited due to its non-specific nature.